<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482989</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP152</org_study_id>
    <nct_id>NCT00482989</nct_id>
    <nct_alias>NCT00566163</nct_alias>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of multiple IV doses of the MEDIMUNNE antibody in&#xD;
      adult patients with SLE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of multiple IV&#xD;
      doses of MEDI-545 in adult patients with SLE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of MEDI-545 will be assessed primarily by summarizing AEs and by assessing changes in viral cultures and titers.</measure>
    <time_frame>Through Study Day 350.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints of this study are the PK and IM of multiple IV doses of MEDI-545. PK parameters, such as peak concentration.</measure>
    <time_frame>Study day 350.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Lupus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-545</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI 545</intervention_name>
    <description>MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.&#xD;
Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.&#xD;
Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults ≥ 18 years of age at the time of the first dose of study drug;&#xD;
&#xD;
          -  Written informed consent obtained from the patient; or patient's legal representative;&#xD;
&#xD;
          -  Meet at least 4 of the 11 revised ACR classification criteria for SLE (see Appendix A)&#xD;
             (ACR,1999);&#xD;
&#xD;
          -  Have positive ANA test at ≥ 1:80 serum dilution in the past or at screening;&#xD;
&#xD;
          -  Have at least one system with a score of A or two systems with a score of B on the&#xD;
             BILAG index at screening, or have a SELENA-SLEDAI score ≥ 6;&#xD;
&#xD;
          -  Sexually active women, unless surgically sterile (including tubal ligation) or at&#xD;
             least 2 years post-menopausal, must use an effective method of avoiding pregnancy&#xD;
             (including oral, injectable, transdermal, or implanted contraceptives, intrauterine&#xD;
             device, diaphragm with spermicide, cervical cap, abstinence, sterile sexual partner)&#xD;
             in addition to the use of condoms (male or female condoms with spermicide) from&#xD;
             screening through the end of the study. Cessation of birth control after this point&#xD;
             should be discussed with a responsible physician. Sexually active men, unless&#xD;
             surgically sterile, must likewise practice two effective methods of birth control&#xD;
             (condom with spermicide or abstinence) and must use such precautions from Study Day 0&#xD;
             through the end of the study.&#xD;
&#xD;
          -  Ability to complete the study period, including follow-up period through Study Day&#xD;
             350; and&#xD;
&#xD;
          -  Willing to forego other forms of experimental treatment during study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received MEDI-545 within 120 days prior to screening or have either detectable&#xD;
             levels of MEDI-545 or anti-MEDI-545 antibodies (positive at &gt; 1:10 serum dilution) in&#xD;
             serum at screening;&#xD;
&#xD;
          -  History of allergy or reaction to any component of the study drug formulation;&#xD;
&#xD;
          -  Have received prednisone &gt; 20 mg/day (or an equivalent dose of another oral&#xD;
             corticosteroid)within 14 days before randomization/entry;&#xD;
&#xD;
          -  Have received the following dosages of medications within 28 days before&#xD;
             randomization/entry: hydroxychloroquine &gt; 600 mg/day, mycophenolate mofetil &gt; 3&#xD;
             g/day,methotrexate &gt; 25 mg/week, azathioprine &gt; 3 mg/kg/day, or any dose of&#xD;
             cyclophosphamide, cyclosporine, or thalidomide;&#xD;
&#xD;
          -  Have received leflunomide &gt;20 mg/day in the 6 months prior to Study Day 0;&#xD;
&#xD;
          -  Have received fluctuating doses of antimalarials, mycophenolate mofetil,&#xD;
             methotrexate,leflunomide, or azathioprine within 28 days before randomization/entry or&#xD;
             fluctuating doses of NSAIDs or oral corticosteroids within 14 days before&#xD;
             randomization/entry;&#xD;
&#xD;
          -  Treatment with any investigational drug therapy within 28 days before&#xD;
             randomization/entry into the study, B cell-depleting therapies within 12 months before&#xD;
             randomization/entry, or biologic therapies within 30 days or 5 half-lives of the&#xD;
             biologic agent, whichever is longer,before randomization/entry into the study;&#xD;
&#xD;
          -  In the investigator's opinion, evidence of clinically significant active infection,&#xD;
             including ongoing, chronic infection, within 28 days before randomization/entry;&#xD;
&#xD;
          -  A history of severe viral infection as judged by the investigators, including severe&#xD;
             infections of either cytomegalovirus or the herpes family such as disseminated herpes,&#xD;
             herpes encephalitis, ophthalmic herpes;&#xD;
&#xD;
          -  Herpes zoster infection within 3 months before randomization/entry;&#xD;
&#xD;
          -  Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active&#xD;
             infection with hepatitis A, as determined by results of testing at screening;&#xD;
&#xD;
          -  Vaccination with live attenuated viruses within 28 days before randomization/entry;&#xD;
&#xD;
          -  Pregnancy (women, unless surgically sterile or at least 2 years post-menopausal, must&#xD;
             have a negative serum pregnancy test within 28 days before receiving the study drug&#xD;
             and a negative urine pregnancy test on Study Day 0 before receiving the study drug);&#xD;
&#xD;
          -  Breastfeeding or lactating women;&#xD;
&#xD;
          -  History of primary immunodeficiency;&#xD;
&#xD;
          -  History of alcohol or drug abuse &lt; 1 year prior to randomization/entry;&#xD;
&#xD;
          -  History of cancer (except basal cell carcinoma or in situ carcinoma of the cervix&#xD;
             treated with apparent success with curative therapy &gt; 1 year prior to&#xD;
             randomization/entry);&#xD;
&#xD;
          -  History of active TB infection;&#xD;
&#xD;
          -  History of latent TB infection or newly positive TB skin test (reaction defined as ≥&#xD;
             10 mm in diameter if not on systemic immunosuppressive medication or ≥ 5 mm if on&#xD;
             systemic immunosuppressive medication) without completion of an appropriate course of&#xD;
             treatment or with ongoing prophylactic therapy;&#xD;
&#xD;
          -  Elective surgery planned from the time of screening through Study Day 196;&#xD;
&#xD;
          -  At screening blood tests (within 28 days before randomization/entry), any of the&#xD;
             following:&#xD;
&#xD;
               -  AST &gt; 2 × upper limit of normal range (ULN), unless caused by SLE, as determined&#xD;
                  by the investigator,&#xD;
&#xD;
               -  ALT &gt; 2 × ULN,unless caused by SLE, as determined by the investigator,&#xD;
&#xD;
               -  Creatinine &gt; 4.0 mg/dL,&#xD;
&#xD;
               -  Neutrophils &quot;1,500/ μL (&lt; 1.5 × 109/L)&quot;&#xD;
&#xD;
               -  Platelet count &quot;Platelet count &lt; 50,000/ μL (&lt; 50 × 109/L)&quot;&#xD;
&#xD;
          -  History of any disease, evidence of any current disease (other than SLE), any finding&#xD;
             upon physical examination, or any laboratory abnormality that, in the opinion of the&#xD;
             investigator or medical monitor, may compromise the safety of the patient in the study&#xD;
             or confound the analysis of the study; or&#xD;
&#xD;
          -  Any employee of the research site who is involved with the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Greth, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0943</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>37765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucuman</city>
        <zip>T4000AXXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2007</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sifalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

